SCHEMBL659548

SCHEMBL659548

c1cc2cnncc2s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29900091 1.00
SCHEMBL10970 0.70
SCHEMBL88594 0.70
SCHEMBL29788434 0.70
Hydrochloric Acid SCHEMBL10877970 0.69 CYP2A6 (0.40)
Potassium SCHEMBL17350115 0.69 CYP2A6 (0.40)
SCHEMBL17350114 0.69 CYP2A6 (0.40)
Hydrochloric Acid SCHEMBL3872997 0.69 CYP2A6 (0.40)
SCHEMBL11068559 0.69 CYP2A6 (0.40)
Lithium SCHEMBL11068561 0.69 CYP2A6 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 US claimed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 US claimed
EP-4087561-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2022-11-16 EP claimed
EP-4087563-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2022-11-16 EP claimed
CN-119775321-A 4, 7-Diaryl thieno [2,3-d ] pyridazine iridium complex, and preparation method and application thereof 湖北文理学院 2025-04-08 CN disclosed
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
EP-3801499-B1 INHIBITORS OF SARM1 DISARM THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20240009190-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2024-01-11 US disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 EP disclosed
US-20230049029-A1 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2023-02-16 US disclosed
EP-4087561-A2 COMBINATION CANCER THERAPY USING CHK INHIBITOR Shanghai Huayu Biotechnology Co., Ltd. (CN) 2022-11-16 EP disclosed
US-7166408-B2 Image forming method using photothermographic material FUJIFILM CORPORATION (JP) 2007-01-23 US disclosed
US-7166408-B2 Image forming method using photothermographic material FUJIFILM CORPORATION (JP) 2007-01-23 US disclosed
US-20070003885-A1 Black and white photothermographic material and image forming method FUJI PHOTO FILM CO., LTD. 2007-01-04 US disclosed
US-20070003885-A1 Black and white photothermographic material and image forming method FUJI PHOTO FILM CO., LTD. 2007-01-04 US disclosed
CN-1769282-A Substituted pyridines and pyridazines with angiogenesis inhibiting activity BAYER PHARMACEUTICALS CORP (US) 2006-05-10 CN disclosed
CN-1769283-A Substituted pyridines and pyridazines with angiogenesis inhibiting activity BAYER PHARMACEUTICALS CORP (US) 2006-05-10 CN disclosed
CN-1420879-A Substituted pyridines and pyridazines having angiogenesis inhibiting activity BAYER AG (US) 2003-05-28 CN disclosed
CN-88103535-A Tricyclic pyridine ketone derivatives and preparation method thereof 1988-12-28 CN disclosed